
Pulmonary arterial hypertension (PAH) is a rare disease affecting the pulmonary vasculature, leading to increased resistance, right ventricular dysfunction, and reduced survival. Treatment options target nitric oxide, endothelin-1, and prostacyclin pathways. Approved therapies include inhibitors, stimulators, antagonists, analogs, and agonists. Risk assessment guides medication use, with dual therapy recommended for low- and intermediate-risk patients, and triple therapy for high-risk patients. Combination therapy may be less effective in patients with comorbidities. Supportive treatments like oxygen, diuretics, and rehabilitation are important. Refractory cases may require lung transplantation. New therapies to improve outcomes are needed for this often fatal condition.
Like
Save
Share